Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Omecamtiv Mecarbil on QT/QTc Intervals in Healthy Subjects
NCT04175808Phase 1Completed
- Sponsor
- Cytokinetics
- Start
- Nov 2019
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of omecamtiv mecarbil in heart failure with reduced ejection fraction (HFrEF) (2 arms), sponsored by Cytokinetics. Primary endpoint: Placebo-corrected Change From Baseline in QT Interval Corrected for Heart Rate Based on the Fridericia Method (QTcF) After Omecamtiv Mecarbil Dosing. Started Nov 2019; status: completed.
02
Drugs
omecamtiv mecarbil
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT04175808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04175808.